Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina
November 12, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
– The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety; 8-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement in...
Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy
November 07, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
– The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared...
Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
January 09, 2023 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase
October 10, 2022 08:00 ET
|
Imbria Pharmaceuticals Inc.
BOSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
American Society of Echocardiography Invests in Joint Research Initiative to Help Patients Suffering from Wide-Reaching Form of Heart Failure
September 29, 2022 09:30 ET
|
American Society of Echocardiography
Durham, NC, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The American Society of Echocardiography (ASE) is targeting its research funding over the next five years to help solve some of the mysteries around...
Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure
July 06, 2022 14:00 ET
|
Tenaya Therapeutics, Inc.
Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms Tenaya’s HDAC6 Inhibitor TN-301 Advancing to the Clinic for HFpEF, with...
Late-breaking Results Show Efficacy for CCM in Patients With HFpEF
May 23, 2022 10:17 ET
|
Impulse Dynamics
MADRID and MARLTON, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a...
Imara Reports Full Year 2021 Financial Results and Business Highlights
March 15, 2022 07:00 ET
|
Imara, Inc.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
March 08, 2022 07:00 ET
|
Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 07:00 ET
|
Imara, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...